【摘要】 目的探究重组人血管内皮抑制素联合顺铂化疗方案在非小细胞肺癌(NSCLC)合并肺不张中的疗效。方法将80例NSCLC合并肺不张患者根据治疗方案的不同分为顺铂化疗组与抑制素组,每组40例。顺铂化疗组应用常规治疗方法及顺铂化疗,抑制素组在顺铂化疗组基础上使用重组人血管内皮抑制素。比较两组患者总生存期、视觉模拟评分法(VAS)评分、卡氏功能状态(KPS)评分、T淋巴细胞亚群水平、血清肿瘤标志物及不良反应发生情况。结果抑制素组患者5年总生存率为38.73%,高于顺铂化疗组的21.08%,差异有统计学意义(χ2=6.87,P﹤0.05)。治疗后,抑制素组患者VAS评分低于顺铂化疗组,KPS评分高于顺铂化疗组;抑制素组CD3+、CD4+水平均高于顺铂化疗组,CD8+水平低于顺铂化疗组;抑制素组患者癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)及鳞状细胞癌抗原(SCCA)水平均低于顺铂化疗组;抑制素组患者不良反应总发生率低于顺铂化疗组,差异均有统计学意义(P﹤0.05)。结论 NSCLC合并肺不张患者治疗中,顺铂化疗方案基础上应用重组人血管内皮抑制素,能够延长患者生存期,缓解患者疼痛,降低CEA、CYFRA21-1及SCCA水平,提高免疫功能,降低不良反应的发生率。更多还原

【Abstract】 Objective To investigate the effect of recombinant human endostatin combined with cisplatin chemotherapy in non-small cell lung cancer with atelectasis. Method A total of 80 patients suffering from NSCLC combined with atelectasis were divided into the cisplatin chemotherapy group and inhibin group according to different treatment schemes, 40 cases in each group. The cisplatin chemotherapy group was treated with conventional treatment and cisplatin chemotherapy, the inhibin group was treated with recombinant human endostatin on the basis of cisplatin chemotherapy group. The overall survival, visual analogue scale(VAS) score, Karnofsky performance status scale(KPS) score, T lymphocyte subset levels, serum tumor markers levels, and adverse events were compared between the two groups. Result The 5-year overall survival in the inhibin group was 38.73%, which was higher than that of 21.08% in the cisplatin chemotherapy group, the difference was statistically significant(χ2=6.87, P<0.05). After treatment, the VAS score of the inhibin group was lower than that of the cisplatin chemotherapy group, and the KPS score was higher than that of the cisplatin chemotherapy group; the CD3+and CD4+levels of the inhibin group were higher than those of the cisplatin chemotherapy group, and the CD8+level was lower than that of the cisplatin chemotherapy group; the levels of carcinoembryonic antigen(CEA), cyto-keratin 19 fragment antigen 21-1(CYFRA21-1) and squamous cell carcinoma antigen(SCCA) in the inhibin group were lower than those in the cisplatin chemotherapy group, the total incidence of adverse events in the inhibin group was lower than that of the cisplatin chemotherapy group, the differences were statistically significant(P<0.05). Conclusion The administration of recombinant human endostatin based on cisplatin chemotherapy in treating NSCLC patients with atelectasis could prolong patients’ survival, relieve theirpain, reduce their CEA, CYFRA21-1 and SCCA levels, improve immune function, and reduce the risk of adverse events.更多还原